Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Aortic Valve Replacement in Patient With Extensive Aortic Dissection: Role of "Balloon Flossing".

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Impact of low testing numbers on chronic wasting disease apparent prevalence.

Prion·2025
Same author

The Value and Challenges of an Ambulatory Intermediate Care Clinic: A Mixed-Methods Analysis.

The Journal of ambulatory care management·2025
Same author

Improved performance of nucleic acid-based assays for genetically diverse norovirus surveillance.

Applied and environmental microbiology·2023
Same author

Version or High Forceps, Which and When?

Buffalo medical journal·2023
Same author

The Impact of Variation in the Toll-like Receptor 3 Gene on Epizootic Hemorrhagic Disease in Illinois Wild White-Tailed Deer (<i>Odocoileus virginianus</i>).

Genes·2023

Related Experiment Video

Updated: Jul 7, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Treating COPD with PDE 4 inhibitors.

William M Brown1

  • 1VaxDesign Corp, Orlando, FL 32826, USA. wbrown@vaxdesign.com

International Journal of Chronic Obstructive Pulmonary Disease
|February 14, 2008
PubMed
Summary
This summary is machine-generated.

Selective phosphodiesterase 4 (PDE 4) inhibitors are being developed to treat chronic obstructive pulmonary disease (COPD). These drugs increase cyclic adenosine monophosphate (cAMP) to reduce inflammation and relax airway muscles.

Related Experiment Videos

Last Updated: Jul 7, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Immunology

Background:

  • Chronic obstructive pulmonary disease (COPD) pathogenesis involves abnormal chronic inflammation with specific immune cell predominance.
  • Elevated cyclic adenosine monophosphate (cAMP) levels can mitigate inflammatory processes.
  • Theophylline, a non-selective phosphodiesterase (PDE) inhibitor, increases cAMP, causing bronchodilation and anti-inflammatory effects.

Purpose of the Study:

  • To review clinical studies of selective PDE 4 inhibitors for COPD treatment.
  • To explore the therapeutic potential of targeting PDE 4 in COPD management.

Main Methods:

  • Review of clinical trial data for PDE 4 inhibitors in COPD.
  • Analysis of PDE 4's role in inflammatory cells and airway smooth muscle.

Main Results:

  • PDE 4 is the primary cAMP-hydrolyzing enzyme in inflammatory and immune cells.
  • Inhibiting PDE 4 increases cAMP, down-regulating inflammation.
  • PDE 4 inhibitors have demonstrated potential in relaxing airway smooth muscle in vitro.

Conclusions:

  • Selective PDE 4 inhibitors represent a promising therapeutic strategy for COPD.
  • Targeting PDE 4 offers a mechanism to reduce inflammation and improve airway function in COPD patients.